NEW YORK, NY / ACCESSWIRE / May 2, 2019 / Bronstein, Gewirtz & Grossman, LLC isinvestigating potential claims on behalf of purchasers of Nabriva Therapeutics PLC ("Nabriva" or the "Company") (NASDAQ: NBRV). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: .
The investigation concerns whether Nabriva and certain of its officers and/or directors have violated federal securities laws.
On this news, Nabriva's stock price fell $0.82 per share, or 27.42%, to close at $2.17 per share on May 1, 2019.
If you are aware of any facts relating to this investigation, or purchased Nabriva shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/nbrv. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Contact:
Bronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC